论文部分内容阅读
目的观察回生口服液辅助治疗肝癌对凝血及纤溶功能影响。方法接受肝动脉化疗栓塞的肝癌患者60例随机分为治疗组和对照组各30例,治疗组患者给予肝动脉化疗栓塞和回生口服液,而对照组患者仅给动脉化疗栓塞。观察2组患者临床疗效,不良反应及凝血和纤溶功能。结果经过观察发现治疗后治疗组患者FIB、D-Dimer和PAI-Ⅰ水平均明显低于对照组,PT、TT和APTT高于对照组(P<0.05)。经过观察发现治疗组患者MPV水平均低于对照组,差异有统计学意义(P<0.01),治疗组患者PLT、PCT和PDW水平高于对照组,差异均有统计学意义(P<0.01)。经过观察发现治疗组患者发生口腔黏膜炎,白细胞减少,血红蛋白减少,恶性呕吐和脱发的患者比例少于对照组患者,但是差异均无统计学意义(P>0.05)。结论回生口服液辅助治疗肝癌可改善患者高凝状态,对临床疗效及不良反应均无明显影响。
Objective To observe the effects of Hui Sheng Oral Liquid on coagulation and fibrinolysis in the treatment of liver cancer. Methods Sixty patients with hepatocellular carcinoma who received hepatic arterial chemoembolization were randomly divided into treatment group (30 cases) and control group (30 cases). Patients in the treatment group received hepatic arterial chemoembolization and rehydration oral liquid, while patients in the control group received only arterial chemoembolization. Clinical efficacy, adverse reactions and coagulation and fibrinolysis were observed in two groups. Results After treatment, the levels of FIB, D-Dimer and PAI-I in the treatment group were significantly lower than those in the control group, and the PT, TT and APTT were higher than those in the control group (P <0.05). After observation, the MPV levels in the treatment group were significantly lower than those in the control group (P <0.01). The PLT, PCT and PDW levels in the treatment group were significantly higher than those in the control group (P <0.01) . After treatment, the incidence of oral mucositis, leukopenia, hemoglobin, vomiting and hair loss in the treatment group was less than that in the control group, but the difference was not statistically significant (P> 0.05). Conclusion Rehydration oral liquid adjuvant treatment of liver cancer can improve the hypercoagulability in patients with no significant effect on clinical efficacy and adverse reactions.